2022.12.08

Press Release

Head Office Relocation to TOKYO TORCH TOKIWABASHI TOWER - Remedy & Company Corporation -

Remedy & Company Corporation (Chiyoda-ku, Tokyo, Founder and CEO Masakuni Ukita) is pleased to announce the relocation of its headquarters to “TOKYO TORCH TOKIWABASHI TOWER” as of January 5th, 2023.

New Office “Entrance A”

In 2005, we founded intellim Corporation, the former of the current Remedy Group, with the vision of "becoming the best CRO in Asia", and we have bult platform of clinical trials not only in Japan but also in East Asia and Southeast Asia.

In order to achieve our vision of building a global health-tech platform, we have further expanding our global capabilities in our CRO business and creating new digital-related services, we have decided to relocate to a central location in Tokyo, where major business has located, with the vision that it will become a starting point for innovation by bringing together a variety of stakeholders from Japan and the world.

◆Office Concept ~Innovation Gateway~

Our office concept is "Innovation Gateway".
We have re-branded company's name in April of this year was made into a new "entrance" to the company, and the "Innovation Gateway" is a space that overlaps with the historical Tokiwabashi-gate, the former "entrance" to Edo Castle, to realize our passion to "provide unprecedented new value and success to all customers by generating innovation. we made it our office concept.

◆ Image of new office

Entrance B
Conference Room

Prayers Room

We have set up a new player room to accommodate the diversity of our employees. We respect each other's cultures and aim to create a comfortable working environment.

VR Room

We have set up a showroom where you can experience the Metaverse space that we have developed in-house. The purpose is to create an environment where employees can freely experience VR.

◆ New Office Outline

Exterior view of Tokiwabashi Tower
New Head Office: TOKYO TORCH Tokiwabashi Tower 23F
New Address: 2-6-4, Otemachi, Chiyoda-ku, Tokyo, Japan 100-0004
Access:

■By train

・Metro

  • 1 minute walk from Exit B8a of Otemachi Station on the Tokyo Metro Chiyoda Line, Marunouchi Line, Hanzomon Line, Tozai Line, and Toei Mita Line
  • 1 minute walk from Exit B2 of Mitsukoshimae Station on the Tokyo Metro Ginza Line/Hanzomon Line
  • 1 minute walk from Exit A1 of Nihombashi Station on the Tokyo Metro Ginza Line, Tozai Line, and Toei Asakusa Line
  • 1 minute walk from Tokyo Metro Marunouchi Line "Tokyo" Station (via JR "Tokyo" Station Nihombashi Exit)

・JR

1 minute walk from Nihombashi Exit of JR Tokyo Station

■By Shinkansen

1 minute walk from Nihombashi Exit of JR Tokyo Station

About Remedy & Company:
Remedy & Company Corporation (formerly known as intellim Holdings Corporation) was established in 2018. Its predecessor, intellim Corporation, which was founded in 2005 with main aim of developing CRO business. Subsequently, intellim Holdings Corporation (now known as Remedy & Company Corporation) was established in 2018 as the core driving intellim Corporation and other group companies in Japan and abroad to create innovative solutions in drug development within Japan and abroad.
In April 2022, the company changed its name to Remedy & Company Corporation and made a new start with the goal of becoming a global health tech platform that transcends the boundaries of a CRO.
Remedy oversees group companies including intellim Corporation, iRIS Corporation, Quantum Healthcare Corporation and Remedy XR Corporation, and its business objective is to achieve further growth for the world, healthcare, and customers, while utilizing the latest technology and innovation.
We currently have offices in 7 countries. (as of November 2022)
For more information, please visit our website: https://www.remedy-company.com/en/

<Contact for Press release>
Remedy & Company Corporation PR Group
E-mail: